Zevra Therapeutics Independent Director Acquires 100% More Stock
Zevra Therapeutics Independent Director Acquires 100% More Stock
Whilst it may not be a huge deal, we thought it was good to see that the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Independent Director, Thomas Anderson, recently bought US$68k worth of stock, for US$6.81 per share. Even though that isn't a massive buy, it did increase their holding by 100%, which is arguably a good sign.
雖然這可能不是什麼大事，但我們認爲看到Zevra Therapeutics, Inc.（納斯達克：ZVRA）的獨立董事Thomas Anderson最近以每股6.81美元的價格買入價值6.8萬美元的股票是一件好事。 儘管這不是一筆巨額購買，但他們的持股增加了100％，這可能是一個好跡象。
Zevra Therapeutics Insider Transactions Over The Last Year
過去一年中，Zevra Therapeutics內部交易情況
In fact, the recent purchase by Thomas Anderson was the biggest purchase of Zevra Therapeutics shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$6.54). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
事實上，根據我們的記錄，Thomas Anderson最近的購買是Zevra Therapeutics內部個人在過去十二個月中進行的最大購買。顯然，內部人士想買，即使比當前股價更高（爲6.54美元）。儘管自購買以來他們的觀點可能已經改變，但至少這表明他們對公司的未來有信懇智能。 在我們看來，內部人員購買股票的價格非常重要。如果他們支付的價格高於當前價格，這通常更鼓舞人心，因爲它表明他們認爲即使在更高的水平上也有價值。
In the last twelve months Zevra Therapeutics insiders were buying shares, but not selling. Their average price was about US$5.65. It is certainly positive to see that insiders have invested their own money in the company. But we must note that the investments were made at well below today's share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
在過去的十二個月中，Zevra Therapeutics內部人士購買了股票，但沒有出售。 他們的平均價格約爲5.65美元。看到內部人員用自己的錢投資公司肯定是積極的。但是我們必須注意，這些投資是在遠低於今天的股價的水平進行的。 您可以在下面的圖表中查看過去一年內的內部交易（由公司和個人進行）。 通過單擊下面的圖表，您可以查看每個內部交易的詳細信息！
Zevra Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Zevra Therapeutics不是唯一一個內部人員購買的股票。因此，請查看這個帶有內部人員購買的潛在公司的免費列表。
Does Zevra Therapeutics Boast High Insider Ownership?
Zevra Therapeutics擁有高內部股權嗎？
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that Zevra Therapeutics insiders own 7.8% of the company, worth about US$20m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
許多投資者喜歡檢查公司由內部人員擁有的股份比例。我們通常希望看到相當高水平的內部持股。顯然，Zevra Therapeutics內部人員擁有7.8％的股份，價值約爲2000萬美元。這種內部持股的水平很高，但仍有些不足。它肯定暗示着合理的對齊度。
So What Do The Zevra Therapeutics Insider Transactions Indicate?
Zevra Therapeutics內部交易的含義是什麼？
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Zevra Therapeutics insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Zevra Therapeutics. In terms of investment risks, we've identified 1 warning sign with Zevra Therapeutics and understanding it should be part of your investment process.
最近的購買非常好。長期的內部交易也增加了我們的信心。但是，我們注意到公司過去十二個月沒有盈利，這使我們謹慎。當與值得注意的內部持股結合在一起時，這些因素表明Zevra Therapeutics內部人員的利益與投資組合非常一致，他們可能認爲股價過低。 除了了解正在進行的內部交易外，還有助於確定Zevra Therapeutics面臨的風險。就投資風險而言，我們已經確定了Zevra Therapeutics的1個警示信號，並且了解它應該是您投資過程的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然，您可能會在其他地方找到一項出色的投資。因此，請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。